Assessment of Health State Utilities Associated With Treatment for Chronic Hepatitis B Virus (HBV) Infection
Author(s)
Louis S. Matza, PhD1, Alan Martin, MSc2, Timothy A. Howell, MA1, Fulya Sen Nikitas, MSc2, Kejsi Begaj, PharmD MS3, Dickens Theodore, MD4, Kosh Agarwal, MD5, Mark Sulkowski, MD6, Carla S. Coffin, MD, MSc7, Grace Dolman, PhD8, Stuart Kendrick, PhD8, Joyeta Das, MPharm2, Afisi S. Ismaila, PhD3.
1Thermo Fisher Scientific, Waltham, MA, USA, 2GSK, London, United Kingdom, 3GSK, Collegeville, PA, USA, 4GSK, Durham, NC, USA, 5Institute of Liver Studies, King’s College Hospital, London, United Kingdom, 6Johns Hopkins University School of Medicine, Baltimore, MD, USA, 7Cumming School of Medicine, Snyder Institute, University of Calgary, Calgary, AB, Canada, 8GSK, Stevenage, United Kingdom.
1Thermo Fisher Scientific, Waltham, MA, USA, 2GSK, London, United Kingdom, 3GSK, Collegeville, PA, USA, 4GSK, Durham, NC, USA, 5Institute of Liver Studies, King’s College Hospital, London, United Kingdom, 6Johns Hopkins University School of Medicine, Baltimore, MD, USA, 7Cumming School of Medicine, Snyder Institute, University of Calgary, Calgary, AB, Canada, 8GSK, Stevenage, United Kingdom.
OBJECTIVES: Hepatitis B virus (HBV) infection management typically requires use of sustained, lifelong medication with nucleos(t)ide analogues (NAs). New treatments, such as bepirovirsen (an unconjugated antisense oligonucleotide currently in Phase 3 studies), are being developed with the goal of functional cure (i.e., long-term HBV surface antigen loss and undetectable HBV DNA after cessation of therapy). Cost-utility analyses will be needed to examine the value of these new treatments and will require health state utilities as inputs. This study estimated health state utilities associated with various treatment and disease states of chronic HBV infection.
METHODS: Seven health state vignettes depicting a range of treatments and chronic HBV infection disease states were drafted based on published literature and clinician and patient interviews. Health states were valued in time trade-off interviews (10-year time horizon) with general population respondents from two UK locations. Utilities were estimated on a scale anchored with 0 representing dead and 1 representing full health.
RESULTS: In total, 216 participants completed interviews (49.5% female; mean [standard deviation (SD)] age = 47.6 [16.2] years). Mean (SD) utilities were 0.938 (0.077) for functional cure, 0.921 (0.089) for NA cessation (i.e., a post-treatment state where NAs have been stopped because functional cure is possible, but monitoring is still necessary to confirm that relapse has not occurred), 0.869 (0.135) during NA treatment, 0.852 (0.156) during treatment with bepirovirsen and NAs, 0.786 (0.251) for untreated HBV, 0.643 (0.310) during treatment with pegylated interferon (Peg-IFN) and NAs, and 0.642 (0.306) during treatment with Peg-IFN.
CONCLUSIONS: The highest utilities were found for health states describing functional cure and the period immediately preceding functional cure (NA cessation). Health states describing treatment with Peg-IFN had the lowest utilities, possibly due to drug-associated adverse events. Information from this study may be useful in models examining cost-effectiveness of HBV treatments. Funding: GSK (212751).
METHODS: Seven health state vignettes depicting a range of treatments and chronic HBV infection disease states were drafted based on published literature and clinician and patient interviews. Health states were valued in time trade-off interviews (10-year time horizon) with general population respondents from two UK locations. Utilities were estimated on a scale anchored with 0 representing dead and 1 representing full health.
RESULTS: In total, 216 participants completed interviews (49.5% female; mean [standard deviation (SD)] age = 47.6 [16.2] years). Mean (SD) utilities were 0.938 (0.077) for functional cure, 0.921 (0.089) for NA cessation (i.e., a post-treatment state where NAs have been stopped because functional cure is possible, but monitoring is still necessary to confirm that relapse has not occurred), 0.869 (0.135) during NA treatment, 0.852 (0.156) during treatment with bepirovirsen and NAs, 0.786 (0.251) for untreated HBV, 0.643 (0.310) during treatment with pegylated interferon (Peg-IFN) and NAs, and 0.642 (0.306) during treatment with Peg-IFN.
CONCLUSIONS: The highest utilities were found for health states describing functional cure and the period immediately preceding functional cure (NA cessation). Health states describing treatment with Peg-IFN had the lowest utilities, possibly due to drug-associated adverse events. Information from this study may be useful in models examining cost-effectiveness of HBV treatments. Funding: GSK (212751).
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE67
Topic
Economic Evaluation
Disease
Infectious Disease (non-vaccine)